{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-015519","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.760086+00:00","generated_at":"2026-05-30T00:48:52.592267+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Capricor reports Q3 net loss $12.6M; starts BLA for deramiocel, signs $715M European deal","bullets":["Q3 net loss $12.6M ($0.38/sh) vs $6.4M ($0.25/sh); revenue $2.3M vs $6.2M.","Began rolling BLA submission for deramiocel (DMD cardiomyopathy) Oct 2024; full submission expected year-end; PDUFA H2 2025.","Signed binding term sheet with Nippon Shinyaku for Europe: $20M upfront, up to $715M milestones plus double-digit revenue share.","Public offering net proceeds ~$80.8M; cash $85M at Sep 30; runway into 2027.","Nippon Shinyaku purchased ~$15M of CAPR stock at 20% premium."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-015519","json":"https://secwatch.observer/filing/0001558370-24-015519.json","markdown":"https://secwatch.observer/filing/0001558370-24-015519.md","text":"https://secwatch.observer/filing/0001558370-24-015519.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024015519/0001558370-24-015519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024015519/capr-20241113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:48:52.592267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}